Lindbrook Capital, LLC Alx Oncology Holdings Inc Transaction History

Lindbrook Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$4.81 - $15.38 $1,356 - $4,337	282 New	282 $4,000
Q2 2022 Aug 01, 2022	BUY	$5.89 - $19.46 $477 - $1,576	81 Added 60.45%	215 $2,000
Q1 2022 Apr 21, 2022	BUY	$13.65 - $22.06 $1,829 - $2,956	134 New	134 $2,000
Q4 2021 Jan 18, 2022	SELL	$21.49 - $74.4 $8,596 - $29,760	-400 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$52.51 - $80.91 $42,008 - $64,728	-800 Reduced 66.67%	400 $30,000
Q2 2021 Jul 27, 2021	BUY	$52.2 - $75.23 $62,640 - $90,276	1,200 New	1,200 $66,000
Q1 2021 Apr 28, 2021	SELL	$62.84 - $87.68 $43,988 - $61,376	-700 Closed	0 $0
Q4 2020 Jan 27, 2021	BUY	$34.11 - $112.26 $18,760 - $61,743	550 Added 366.67%	700 $60,000
Q3 2020 Nov 03, 2020	BUY	$29.36 - $47.1 $4,404 - $7,065	150 New	150 $6,000

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $66M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.